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Activating mutations in KIT have been identified in melanomas of acral
and mucosal types and in those arising in chronically sun-damaged skin.
Until now, KIT has been considered an oncogenic driver and a potential
therapeutic target. However, data presented by Dhal et al. show that in cutaneous
melanomas the KIT promoter is a target for hypermethylation, leading to its
downregulation. Their observations suggest that signaling pathways downstream
of KIT may have distinct and opposing roles in the pathogenesis of melanoma
subtypes. This will have important implications for the use of KIT inhibitors in
treating melanomas.
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KIT (c-kit), a type III receptor tyrosine
kinase, and its ligand, stem cell factor
(SCF), also known as c-kit ligand, are
essential for the development of mela-
nocytes in vertebrates, regulating
growth, migration, survival, and
differentiation (Wehrle-Haller, 2003).
Their importance is highlighted by the
development of pigmentation disorders
upon loss of function in both mice
and humans. The rare autosomal
dominant disorder piebaldism, chara-
cterized by congenital patchy depig-
mentation of the skin, is attributed to
heterozygous inactivating mutations in
the KIT gene.
Activation of the KIT receptor is
achieved through rapid homodimeriza-
tion induced by SCF binding, follo-
wed by a cascade of auto-inhibitory
interactions, transphosphorylation, and
recruitment and activation of multiple
downstream effectors (reviewed in
Lennartsson and Ronnstrand, 2012).
Depending on the cellular context in
which KIT is activated, downstream
effectors include Src family kinases, the
p85 subunit of PI3K, phospholipase
C-gamma, and MAP kinases. Recently,
it has been demonstrated that Y568 and
Y570 in the juxtamembrane region
of KIT, which are involved in activation
of Src, are required for normal
pigmentation via regulation of MITF
(Phung et al., 2011).
Even though established as a critical
mitogen for melanocytes, earlier studies
of KIT protein in melanoma suggested
that it is lost during disease progression;
this was based on its higher expression
in benign nevi vs primary and metastatic
melanoma (Montone et al., 1997; Isabel
Zhu and Fitzpatrick, 2006). Also, early
in vitro studies indicated that KIT might
have a tumor-suppressing role in mela-
noma because it was lost in the majority
of melanoma cell lines. In addition,
melanoma xenografts with low KIT
expression displayed higher metastatic
potential, whereas ectopic KIT expre-
ssion in KIT-deficient lines inhibited
growth of these cells in vivo (Huang
et al., 1996). At the same time, however,
KIT was assigned a clear oncogenic role
in many other tumor types, includ-
ing gastrointestinal stromal tumors
(GISTs), small-cell lung carcinomas, and
acute myeloid leukemia, where
activating KIT mutations were seen in
as many as 70–80% of cases. For
this reason, identification of KIT ampli-
fications and activating mutations in
selected melanoma subtypes generates
great excitement in melanoma research
and clinical communities as a potential
target for therapy.
KIT mutations or amplifications are
observed in B30% of mucosal, 20%
of acral, and 20% of melanomas arising
in chronically sun-damaged skin
(Curtin et al., 2006; Beadling et al.,
2008). Although most mutations
detected in BRAF and NRAS genes
occur in single codons, V600 and
Q61, respectively, KIT mutations show
heterogeneous distribution thorough the
gene, and they are detected most
frequently in exon 11 (L576P) and
exon 13 (K642E). In early studies, no
KIT mutations were found in melano-
mas arising from non-chronically sun-
damaged skin. Unfortunately, these
were the majority of patients included
in the first trials with KIT inhibitors
(Ugurel et al., 2005; Wyman et al.,
2006; Kim et al., 2008). For this
reason, most patients failed to demon-
strate significant responses. More
recently, however, substantial tumor
responses were reported with imatinib
mesylate and dasatinib in patients
with melanomas harboring KIT
alterations, including a K642E and
L576P mutation as well as a 7-codon
duplication of exon 11 (Hodi et al.,
2008; Lutzky et al., 2008; Quintas-
Cardama et al., 2008; Woodman et al.,
2009).
The discrepancies between early and
more recent studies reflect the complex-
ity of KIT function in melanoma, sug-
gesting that they vary under specific
cellular and microenvironmental condi-
tions. In the current issue of the Journal
of Investigative Dermatology, Dahl et al.
focus on the tumor-suppressive func-
tions of KIT. The authors use genome-
wide promoter profiling to identify
DNA-methylation changes that impact
gene expression in melanoma cell lines
and uncultured cutaneous melanomas.
Their results, verified by using several
approaches, show that the KIT promoter
is highly methylated in melanoma cell
lines and that this methylation is a
frequent cause of transcriptional silen-
cing of the gene. More importantly, the
authors demonstrate that KIT hyper-
methylation is not an in vitro artifact
but is also observed in uncultured
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melanomas. It appears that SCF expo-
sure over time can induce epigenetic
downregulation of KIT, suggesting the
existence of a fine-tuned balance
between different consequences
of KIT activation. Interestingly, the
authors did not find any correlation of
KIT activation with well-documented
melanoma drivers, including the
BRAF and NRAS pathways, even though
these have previously been found
to be mutually exclusive. Together,
these observations suggest that KIT
might be mediating its effects via an
unidentified and independent molecular
pathway.
Their study provides strong support
for the previously suggested, but mostly
ignored, possibility that KIT has a tumor-
suppressive role in melanomas that
occur on intermittently sun-exposed
skin with frequent BRAF and NRAS
mutations. Co-expression of these two
mutations in human melanoma cells is
shown to induce senescence (Petti et al.,
2006). For this reason and as suggested
by Dahl et al., it is possible that down-
regulation of KIT during melanoma
progression might favor avoidance of
hyperstimulation via the ERK1/2
pathway, thereby leading to cell cycle
arrest and senescence.
In other cell types, it is well estab-
lished that KIT ligand SCF acts synergis-
tically with other cytokines, including
IL-3, IL-7, and Epo, in part via direct
interactions with their respective
receptors (reviewed in Lennartsson and
Ronnstrand, 2012). Recently, it was
shown that activation of the human G
protein–coupled melanocortin 1 recep-
tor (MC1R) leads to ERK1/2 phosphor-
ylation by a mechanism involving Src-
mediated transphosphorylation of KIT,
suggesting crosstalk between these path-
ways (Herraiz et al., 2011). Whether
similar types of interaction could
account for KIT’s tumor-suppressor
functions and whether this is relevant
to melanoma, remains to be investi-
gated.
This study provides yet another
example of the extraordinary molecular
diversity of melanomas, empha-
sizing the need for careful molecular
profiling of these tumors before choos-
ing therapies.
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Clinical Implications
 The functional role of KIT in melanoma development and progression
appears to be dependent on melanocyte anatomical location.
 In a subtype of cutaneous melanoma, KIT is frequently lost because
of hypermethylation, suggesting that it might have a tumor-suppressive
role.
 Clinical KIT inhibitors might have undesirable effects by accelerating the
progression of early-stage cutaneous melanomas that are growth inhibited
because of intrinsic expression of KIT.
 KIT inhibitors should only be considered for treatment of correctly
subtyped and molecularly defined melanomas with confirmed KIT
status.
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